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A B S T R A C T
Background
Worldwide, vaginal transmission now accounts for more than half of newly acquired HIV-1
infections. Despite the urgency to develop and implement novel approaches capable of
preventing HIV transmission, this process has been hindered by the lack of adequate small
animal models for preclinical efficacy and safety testing. Given the importance of this route of
transmission, we investigated the susceptibility of humanized mice to intravaginal HIV-1
infection.
Methods and Findings
We show that the female reproductive tract of humanized bone marrow–liver–thymus (BLT)
mice is reconstituted with human CD4þ T and other relevant human cells, rendering these
humanized mice susceptible to intravaginal infection by HIV-1. Effects of HIV-1 infection include
CD4þ T cell depletion in gut-associated lymphoid tissue (GALT) that closely mimics what is
observed in HIV-1–infected humans. We also show that pre-exposure prophylaxis with
antiretroviral drugs is a highly effective method for preventing vaginal HIV-1 transmission.
Whereas 88% (7/8) of BLT mice inoculated vaginally with HIV-1 became infected, none of the
animals (0/5) given pre-exposure prophylaxis of emtricitabine (FTC)/tenofovir disoproxil
fumarate (TDF) showed evidence of infection (Chi square ¼ 7.5, df¼ 1, p ¼ 0.006).
Conclusions
The fact that humanized BLT mice are susceptible to intravaginal infection makes this system
an excellent candidate for preclinical evaluation of both microbicides and pre-exposure
prophylactic regimens. The utility of humanized mice to study intravaginal HIV-1 transmission is
particularly highlighted by the demonstration that pre-exposure prophylaxis can prevent
intravaginal HIV-1 transmission in the BLT mouse model.
The Editors’ Summary of this article follows the references.
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Introduction
HIV, the causative agent of AIDS, is predominantly
transmitted by unprotected sexual contact [1]. Currently,
women worldwide account for more than half of the
estimated 6,800 newly acquired infections every day, with a
majority of those transmissions occurring via the vaginal
route [1]. Therefore, it is critical that strategies to prevent
vaginal transmission of HIV be developed and implemented.
Without an effective vaccine on the horizon, alternative
strategies are urgently needed to prevent the further spread
of AIDS. Development and efficacy testing of microbicides
and other preventive strategies, such as antiretroviral pre-
exposure prophylaxis, necessitate animal models [2–5].
Currently, the only surrogate animal model used to study
intravaginal HIV transmission are macaques infected with
simian immunodeficiency virus (SIV) or SIV/HIV (SHIV)
chimeric viruses [6,7]. This model recapitulates several
aspects of human infection, but does not support HIV-1
replication. In addition, the expense of non-human primate
experiments is high, the availability of animals (especially
females) is limited, and variations in host susceptibility along
with disease progression occur because non-human primate
colonies are outbred. Consequently, there is significant need
to develop animal models to investigate measures to prevent
intravaginal HIV-1 transmission.
Using humanized mice to address this need is attractive
because they allow in vivo studies of HIV-1 infection of
human cells. In addition, in vivo preclinical evaluation of
potential clinical interventions can minimize human risk [8].
A common aspect of producing humanized mice is trans-
planting human hematopoietic stem cells (HSC) into one of
several immunodeficient mouse strains (reviewed in [8]). The
mouse age at transplant and anatomical locations of the
transplants vary by model, but in each system, the trans-
planted HSC engraft the mouse bone marrow. These
engrafted HSC then differentiate in situ into human
hematopoietic lineages including T, B, myeloid, and dendritic
cells [9,10]. It should be noted that in this context, human
thymocytes are generated in the mouse thymus and in the
absence of human thymic stroma. Alternatively, human
thymocytes can develop in the context of human thymus in
the SCID-hu thy/liv mouse model [11,12], which has been used
to evaluate the efficacy of antiretrovirals, including emtrici-
tabine (FTC), efavirenz, atazanavir, and enfuvirtide [13]. The
SCID-hu thy/liv model does not incorporate transplantation
of human HSC into the recipient mouse; it involves only
implantation of human fetal thymus and liver beneath the
kidney capsule of SCID mice. A human thymus complete with
human thymocytes is generated, yet systemic reconstitution
of SCID-hu thy/liv mice with human hematopoietic cells is
sparse and limited to T cells [14].
Humanized bone marrow–liver–thymus (BLT) mice [15]
represent advancement beyond these models. Humanized
BLT mice are generated by initially implanting human fetal
liver and thymus tissue under the kidney capsule of an
immunodeficient mouse (as with SCID-hu thy/liv), followed by
an autologous human HSC transplant of human fetal liver
CD34þ cells (similar to other humanization protocols). Thus,
humanized BLT mice combine the most desirable attributes
of other humanized mouse models into a single system.
Namely, in humanized BLT mice, there is human thymic
tissue where T cell education occurs, and there is complete
systemic reconstitution of all major human hematopoietic
lineages, including T, B, monocyte/macrophage, dendritic,
and natural killer cells [15]. In addition, BLT mice have been
shown to mount robust human immune responses, such as
antigen-specific human immunoglobulin G (IgG) production
[16] and xenograft rejection [17]. Human T cells in BLT mice
can generate human leukocyte antigen class I– and class II–
restricted adaptive immune responses to Epstein-Barr virus
and are activated by human dendritic cells to mount a potent
T cell immune response to superantigens [15]. Particularly
relevant to this study is the extensive reconstitution of
lymphoid tissue within the gut of humanized BLT mice
[15,16]. With this particular finding in mind, we hypothesized
that mucosal reconstitution with human lymphoid cells would
be systemic and would include the female reproductive tract
(FRT), rendering female BLT mice susceptible to intravaginal
HIV-1 infection.
To conclusively address these hypotheses, we designed the
present study. Our aims were to (1) characterize the
reconstitution of the FRT with human lymphoid cells; (2) test
the susceptibility of humanized BLT mice to viral trans-
mission following a single intravaginal exposure to cell-free
HIV-1; (3) characterize systemic pathogenic effects of HIV-1
transmitted intravaginally and disseminated throughout
humanized BLT mice, including effects in the gut-associated
lymphoid tissue (GALT); and (4) utilize this small animal
model to conduct pre-clinical evaluation of antiretroviral pre-
exposure prophylaxis for intravaginal HIV-1 transmission.
Materials and Methods
Preparation of Humanized BLT Mice, Tissue Harvesting,
and Microscopic and Flow Cytometric Analyses
Humanized BLT mice were prepared essentially as we have
previously described [15,16]. Briefly, thy/liv-implanted mice
[12] were transplanted with autologous human fetal liver
CD34þ cells (Advanced Bioscience Resources) and monitored
for human reconstitution in peripheral blood by flow
cytometry as we have previously described [15,16]. Mice were
maintained at the Animal Resources Center of University of
Texas Southwestern Medical Center (UTSWMC) in accord-
ance with protocols approved by the UTSWMC Institutional
Animal Care and Use Committee. Tissues were harvested for
both microscopic and flow cytometric analyses. Immunohis-
tochemical and in situ analyses were performed essentially as
previously described [15,16]. Specific controls for immuno-
histochemistry included staining tissue sections from human-
ized BLT mice with isotype-matched negative control
antibodies (mouse IgG1, mouse IgG2a, goat ChromPure IgG,
and rabbit ChromPure IgG) to demonstrate that appropriate
human lineages were being detected. Conversely, mice never
reconstituted with human cells were stained with anti-human
CD3, CD4, CD68, and CD11c to rule out the staining of any
non-human cells by these antibodies (unpublished data;
[15,16]). Single-cell suspensions for flow cytometric analysis
of each tissue were prepared essentially as we have previously
described [15,16].
Intravaginal Exposure of Humanized BLT Mice to HIV-1
Stocks of HIV-1JR-CSF [18] were prepared, titered, and p24
content determined as we have previously described [19,20].
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Prior to inoculation, mice were anesthetized with sodium
pentobarbital. Atraumatic intravaginal inoculations were
performed essentially as previously described [21] using a
total volume of 10 ll (170 ng of p24, ;93 104 tissue culture
infectious units). FTC and tenofovir disoproxil fumarate
(TDF) (Gilead) were administered intraperitonealy (3.5 mg
and 5.2 mg, respectively) once daily for seven consecutive
days starting 48 h prior to intravaginal inoculation with HIV-
1 [13,22,23].
Analysis of HIV Infection of Humanized BLT Mice
Infection of BLT mice with HIV was monitored in
peripheral blood by determining plasma viral load (Amplicor;
Roche), plasma levels of viral antigenemia (ELISA p24
[sensitivity: 12 pg/ml of diluted mouse plasma]; Coulter) and
by determining the levels of human CD4þ and CD8þ T cells in
peripheral blood (flow cytometry) essentially as we have
previously described [15,16,20]. Analysis of systemic infection
was performed by in situ hybridization and flow cytometry,
also as we have previously described [15,16,24]. Quantitative
real-time PCR for viral DNA was performed using Assays-on-
Demand in a 7500 Fast instrument (sensitivity: five copies of
JR-CSF; SDS software version 1.3.1.22; Applied Biosystems)
following the manufacturer’s protocol for universal cycling
conditions. ABI custom TaqMan reagents were: Forward
primer: 59-ATCAAGCAGCTATGCAAATGCT-39; Reverse
primer: 39-CTGAAGGGTACTAGTAGTCCCTGCTATGTC-
59; and MGB probe: 59-TCAATGAGGAAGCTGCAGAA-39.
Rescue of infectious virus from the indicated tissues was
performed by coculture with PHA/IL2-activated PBMC from
HIV seronegative donors, and viral spread was monitored by
determining p24 levels in the culture supernatant [16].
Human CD4þ T cell depletion was monitored in all tissues
indicated essentially as we have previously described using
six-color flow cytometry (FACSCanto; BD Biosciences) with
analysis performed in FACSDiva software (BD Biosciences)
[16]. Statistical analysis using the Student t test and the
Kaplan-Meier plot were performed using Prism v. 4 (Graph
Pad Software).
Results
The FRT represents a highly specialized and complex
anatomical site where initial infection occurs following
intravaginal exposure [25–27]. Therefore, we used immuno-
histochemistry to determine whether human lymphocytes
and other cells important for HIV-1 infection were present in
the vagina, ectocervix, endocervix, and uterus after recon-
stitution of BLT mice with human HSC. All populations of
human cells necessary for HIV-1 infection (CD4þ T cells,
macrophages, and dendritic cells) were found to be abundant
throughout the FRT of BLT mice (Figure 1). Specifically,
human CD4þ cells were distributed throughout the FRT. Also,
human CD68þ monocyte/macrophage cells and clusters of
human CD11cþ dendritic cells were identified throughout the
FRT. Together, these data establish that in situ differentiation
of human HSC leads to reconstitution of the FRT of BLT
mice with the human hematopoietic cells relevant to mucosal
HIV-1 transmission [28–30].
Figure 1. Reconstitution of the Female Reproductive Tract of Humanized BLT Mice with Human Hematopoietic Cells
Immunohistochemical analysis of the vagina, ectocervix, endocervix, and uterus of female BLT mice for the presence of human hematopoietic lineages
(brown cells) (bars indicate 25 lm). Robust reconstitution with cells relevant to HIV-1 infection, including human T cells, monocyte/macrophages, and
dendritic cells, was observed in each compartment of the FRT of humanized BLT mice, demonstrating the efficient repopulation of these important
mucosal sites.
doi:10.1371/journal.pmed.0050016.g001
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We then tested the susceptibility of humanized BLT mice
to transmission of HIV-1 administered intravaginally. Prior
to HIV-1 exposure, we analyzed the peripheral blood of all
humanized BLT mice to be used in our study (8 to 12 wk post-
transplant) and determined that, on average, slightly more
than half (51.9% 6 7.2%) of all circulating peripheral blood
cells were of human origin. We inoculated BLT mice (n ¼ 8)
with a single dose of cell-free HIV-1 (CCR5-tropic primary
isolate JR-CSF [18]). BLT mice that did not receive HIV-1 (n¼
6) were used as naive controls. In addition, we assessed
intravaginal HIV-1 transmission in BLT mice administered a
7-d course of antiretroviral drugs (n ¼ 5). We used
emtricitabine and tenofovir disoproxil fumarate (FTC/TDF)
because of potency, daily dosing, and favorable profiles for
both toxicity and viral resistance [31]. FTC/TDF was admin-
istered 2 d prior to intravaginal inoculation, 3 h prior to
inoculation, and for 4 d postinoculation. Whereas 88% (7/8)
of BLT mice inoculated with HIV-1 became infected (Figure
2A: Chi square¼ 7.5, df¼ 1, p¼ 0.006), none of the animals (0/
5) that received FTC/TDF showed evidence of infection
(Figure 2A and 2B).
Neither naive nor FTC/TDF-treated BLT mice showed any
Figure 2. Pre-exposure Prophylaxis Prevents Intravaginal HIV-1 Transmission in Humanized BLT Mice
(A) Kaplan-Meier plot of the time course to plasma antigenemia conversion following intravaginal HIV-1 exposure in BLT mice with or without the 7-d
pre-exposure regimen of FTC/TDF (administered once daily starting 48 h prior to intravaginal inoculation).
(B) Plasma from the seven infected BLT mice and the five FTC/TDFþ HIV-1 mice was tested for the presence of HIV-1 RNA. Data presented depict the
initial positive viral RNA value for each mouse examined. The dashed line indicates the limit of detection for this assay.
(C–E) Shown are the levels of human CD4þ (orange squares) and CD8þ (blue circles) T cells in peripheral blood as well as the levels of HIV p24
antigenemia (black triangles) in plasma for (C) naive control (n¼ 6), (D) HIV-1 infected (n¼ 7), and (E) pre-exposure FTC/TDF-treated animals (n¼ 5). In
(D), note that in seven of eight tested BLT mice, a single exposure to HIV-1 led to intravaginal transmission and an initial drop, with subsequent
stabilization, in the levels of peripheral blood CD4þ human T cells. In contrast, no changes were observed in either the naive control (C) or BLT mice that
received FTC/TDF for pre-exposure prophylaxis (E). In (D) and (E), day 0 is the day of inoculation and is indicated by an arrow. Gating strategy for flow
cytometric analysis: live cells ! human CD45 ! human CD3 ! human CD4 or CD8.
(F) Immunohistochemical staining for human CD4þ cells within the vagina of a representative FTC/TDF-treated mouse demonstrating the continued
presence of CD4þ T cells in this tissue (left, bar indicates 50 lm; right, bar indicates 12.5 lm; box indicates region magnified in subsequent image).
doi:10.1371/journal.pmed.0050016.g002
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evidence of plasma antigenemia (Figure 2C and 2E). In
contrast, HIV-1 antigenemia was evident in the plasma from
7/8 intravaginally inoculated BLT mice as early as 2 wk
postinfection (Figure 2D). Infection was corroborated by
determining the viral load in the plasma of infected BLT
mice. On average, 5.03 105 (61.53 105) copies of RNA were
detected per milliliter of plasma from the infected mice
(Figure 2B). The appearance of HIV-1 in the plasma of
infected mice preceded or coincided with a decline in
peripheral blood human CD4þ T cells (Figure 2D). The levels
of CD4þ T cells dropped by 30% during the first 3 wk
postinfection and remained relatively constant for 7 wk, at
which point there was a further 20% decline and an inversion
of the ratio of CD4/CD8 cells (Figure 2D). Parallel to the
decline of CD4þ T cells, there was an increase in the
percentage of human CD8þ T cells in the periphery of
infected BLT mice, which by 11 wk postinfection represented
60% of all the CD3þ cells in the periphery (Figure 2D). To
eliminate the possibility that the lack of HIV-1 infection in
FTC/TDF-treated mice resulted from a deficiency of cells that
could be infected by HIV-1 within the mucosal portal of
entry; the FRT of FTC/TDF-treated mice were examined for
human CD4þ cells. The presence of CD4þ human cells in the
vagina of inoculated mice that received pre-exposure
prophylaxis with FTC/TDF rules out a lack of hematopoietic
reconstitution of the FRT as responsible for the lack of
infection (Figure 2F). Together, these results demonstrate the
striking susceptibility of BLT mice to infection by HIV-1
administered intravaginally and highlight the extensive
similarity in the course of HIV-1 infection in peripheral
blood between BLT mice, humans, and rhesus macaques
(infected with R5-tropic SHIV), including plasma viremia and
CD4þT cell depletion from peripheral blood [32–34]. Perhaps
more important, these data demonstrate that pre-exposure
prophylaxis affords complete protection to humanized BLT
mice from vaginal HIV-1 transmission.
The systemic effects of HIV-1 infection in humans are
inherently difficult to study. Therefore, we took advantage of
the systemic repopulation of BLT mice with human lympho-
cytes to evaluate the effects of HIV-1 infection in relevant
internal organs. Since CD4þ T cell depletion is a hallmark of
HIV-1 infection, we compared the levels of these cells
throughout the body of naive versus HIV-1–infected versus
pre-exposure FTC/TDF-treated BLT mice. No statistical
difference was observed when CD4þ T cell levels of all tissues
combined in naive and pre-exposure FTC/TDF-treated BLT
mice were compared (% Mean1% Mean2 [M1M2]¼ 1.2 6
8.8, t¼0.13, df¼65, p¼0.90). However, when comparing HIV-
1–infected versus FTC/TDF-treated and HIV-1–exposed mice,
statistically significant reductions in CD4þ T cells were noted
in peripheral blood (M1 M2 ¼49 6 13, t ¼ 3.8, df ¼ 5, p ¼
0.012), bone marrow (M1M2¼52 6 4.1, t¼ 13, df¼ 5, p ,
0.001), spleen (M1M2¼36 6 4.7, t¼ 7.5, df¼ 5, p , 0.001),
lymph nodes (M1M2¼28 6 7.4, t¼ 3.7, df¼ 5, p¼ 0.013),
liver (M1M2¼34 6 11, t¼ 3.2, df¼ 5, p¼ 0.024), and lung
(M1  M2 ¼45 6 8.1, t ¼ 5.6, df ¼ 5, p ¼ 0.003) in HIV-1–
infected mice; no significant difference was noted in the
thymic organoid (M1M2¼1.8 6 4.5, t¼0.40, df¼ 5, p¼ 0.70)
(Figure 3A and 3B). Together with the reduction in the levels
of CD4þ human T cells, there was a concomitant statistically
significant increase in the levels of CD8þ human T cells
comparing HIV-1–infected versus FTC/TDF-treated and HIV-
1–exposed mice in all tissues tested, including peripheral
blood (M1  M2 ¼ 45 6 13, t ¼ 3.4, df ¼ 5, p ¼ 0.019), bone
marrow (M1M2¼ 46 6 3.5, t¼ 13, df¼ 5, p , 0.001), thymic
organoid (M1M2¼ 26 6 9.9, t¼ 2.7, df¼ 5, p¼ 0.045), spleen
(M1M2¼296 2.8, t¼10, df¼5, p, 0.001), lymph nodes (M1
M2¼276 7.8, t¼3.4, df¼5, p¼0.019), liver (M1M2¼346
10, t¼ 3.4, df¼ 5, p¼ 0.019), and lung (M1M2¼ 40 6 6.5, t¼
6.2, df ¼ 5, p ¼ 0.002) (Figure 3A and 3C).
CCR5 coreceptor expression levels on human lymphocytes
vary by tissue, with lower levels on peripheral blood, bone
marrow, thymus, spleen, and lymph node lymphocytes and
higher levels in liver, lung, and GALT [16,35–37]. Comparison
of HIV-1–infected versus FTC/TDF-treated and HIV-1–
exposed mice demonstrated a significant reduction of
CD4þCCR5þ T cells in BLT liver (M1  M2 ¼15 6 2.1, t ¼
7.5, df¼5, p , 0.001) and lungs (M1M2¼7.3 6 0.77, t¼ 9.4,
df ¼ 5, p , 0.001); no significant difference was noted in the
peripheral blood (M1 M2 ¼ 0.83 6 2.1, t ¼ 0.40, df ¼ 5, p ¼
0.71), bone marrow (M1M2¼0.33 6 2.1, t¼ 0.16, df¼ 5, p¼
0.88), thymic organoid (M1M2¼1.1 6 0.73, t¼ 1.5, df¼ 5, p
¼0.19), spleen (M1M2¼1.46 0.59, t¼2.4, df¼5, p¼0.060),
or lymph nodes (M1  M2 ¼1.1 6 0.47, t ¼ 2.3, df ¼ 5, p ¼
0.069) (Figure 4A and 4B). We also observed a dramatic
increase, indicative of a heightened state of immune
activation, in the levels of human CD8þCCR5þ T cells in all
tissues in response to HIV-1 infection between HIV-1–
infected versus FTC/TDF-treated and HIV-1–exposed mice
in peripheral blood (M1  M2 ¼ 52 6 16, t ¼ 3.3, df ¼ 5, p ¼
0.022), bone marrow (M1 M2 ¼ 35 6 7.2, t ¼ 4.9, df ¼ 5, p ¼
0.005), thymic organoid (M1M2¼23 6 5.0, t¼ 4.5, df¼5, p¼
0.006), spleen (M1 M2 ¼ 24 6 9.3, t ¼ 2.6, df ¼ 5, p ¼ 0.048),
lymph nodes (M1 M2 ¼ 23 6 7.8, t ¼ 3.0, df ¼ 5, p ¼ 0.031),
liver (M1 M2 ¼ 33 6 12, t ¼ 2.7, df ¼ 5, p ¼ 0.043), and lung
(M1M2¼ 22 6 8.5, t¼ 2.6, df¼ 5, p¼ 0.050) (Figure 4C and
4D). Thus, HIV-1 infection altered the proportions of CCR5þ
T lymphocytes throughout BLT mice. Together, these results
demonstrate that intravaginal HIV-1 transmission in human-
ized BLT mice leads to systemic effects by the virus that
closely mimics what is observed in infected humans.
The GALT is a major site of HIV-1 replication and CD4þ T
cell depletion during HIV disease in humans [38]. Therefore,
we isolated intraepithelial (IEL) and lamina propria (LPL)
lymphocytes from both small and large intestine (SI and LI,
respectively) of BLT mice for analysis. Consistent with what
has been observed during the course of human HIV-1
infection, we also observed a dramatic reduction in CD4þ T
cells in the SI IEL (M1M2¼566 8.0, t¼7.0, df¼6, p, 0.001),
SI LPL (M1M2¼406 4.9, t¼8.3, df¼6, p, 0.001), LI IEL (M1
M2¼236 5.3, t¼4.3, df¼6, p¼0.005), and LI LPL (M1M2¼
49 6 9.3, t ¼ 5.2, df ¼ 6, p ¼ 0.002) (Figure 5A and 5B). As
described above for liver and lung, HIV-1 infection resulted in
a significant reduction of CD4þCCR5þT cells in BLT mouse SI
IEL (M1M2¼216 4.1, t¼5.1, df¼6, p¼0.002), SI LPL (M1
M2¼226 8.5, t¼2.6, df¼6, p¼0.042), LI IEL (M1M2¼386
8.9, t¼4.3, df¼6, p¼0.005), and LI LPL (M1M2¼486 4.4, t¼
11, df¼ 6, p , 0.001) (Figure 5C and 5D). We also observed a
statistically significant reduction in the levels of CD4þ effector
memory T cells (CD45RAnegCD27neg) from the SI IEL (M1 
M2¼ 41 6 11, t¼ 3.7, df¼ 6, p¼ 0.010) and SI LPL (M1M2¼
36 6 12, t¼ 3.1, df¼ 6, p¼ 0.021) of infected BLT mice (Figure
5E–5G). These findings are in agreement with studies in
humans and macaques regarding memory T cell loss in GALT
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by HIV-1 and SIV/SHIV [24,38–41], and highlight the
usefulness of the BLT model for studying HIV-1 pathogenesis,
particularly in GALT.
Finally, to confirm the lack of infection in FTC/TDF-
treated animals shown in Figures 2, 3, and 4, three additional
approaches were utilized. DNA isolated from cells obtained
from different organs of either HIV-1–infected or FTC/TDF-
treated BLT mice was analyzed by quantitative real-time PCR
for HIV-1 viral DNA. Whereas the tissues from HIV-1–
infected mice were clearly positive for viral DNA, samples
from pre-exposure FTC/TDF-treated mice were consistently
negative (Figure 6A). Cells isolated from multiple organs of
HIV-1–infected or FTC/TDF-treated BLT mice were cocul-
tured with PHA/IL2-activated peripheral blood lymphocytes
from a seronegative donor. Virus was readily rescued from
cells isolated from tissues obtained from the HIV-1–infected
mice (Figure 6B). In contrast, no virus was rescued from any
of the tissues obtained from the BLT mice treated with FTC/
TDF. Last, we used in situ hybridization to determine the
presence of productively infected cells in HIV-1–infected or
FTC/TDF-treated BLT mice. Productively HIV-1–infected
cells were readily observed in tissues from the HIV-1–infected
BLT mice (Figure 6C). In contrast, no productively infected
cells were found in any of the tissues from the FTC/TDF-
treated mice. These results verify the protection afforded by
this pre-exposure prophylaxis approach to the prevention of
intravaginal transmission of HIV-1 in BLT mice.
Discussion
The present study demonstrates efficient intravaginal HIV-
1 transmission in humanized BLT mice that results in a
systemic reduction of engrafted human CD4þ T cells and a
loss of GALT effector memory human CD4þ T cells, as has
been observed in humans [24,38–41]. In addition, we provide
evidence of the effectiveness of antiretrovirals for pre-
exposure prophylaxis to prevent intravaginal HIV-1 trans-
mission.
In the absence of an effective vaccine or topical micro-
bicide, alternative preventative measures are desperately
needed to help block the spread of AIDS. Antiretroviral
Figure 3. Systemic CD4þ T Cell Loss Resulting from Intravaginal HIV-1 Infection in Humanized BLT Mice
(A) Comparison of the levels of CD4þ or CD8þ human T cells in the indicated tissues in representative BLT mice that were either naive, HIV-1 infected, or
that received FTC/TDF for pre-exposure prophylaxis prior to exposure to HIV-1. Note the HIV-1 induced reduction in the double-positive CD4þCD8þ
thymocytes.
(B and C) Box plots depicting the levels of CD4þ (B) or CD8þ (C) T cells in the indicated tissues for naive (green), HIV-1 infected (white), and FTC/TDF-
treated plus HIV-1–exposed (red) BLT mice. In these plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data.
The middle line within each box indicates the median of the data, whereas the vertical line extends from lowest to the highest values. Data from naive,
HIV-1-, or FTC/TDF-treated plus HIV-1–exposed mice were not collected on the same day. Naive (n¼5), HIV-1 infected (n¼ 4), and FTC/TDFþHIV-1 (n¼
3). Flow cytometry gating for this figure was performed as described for Figure 2.
BM, bone marrow; LN, lymph node; PB, peripheral blood; Thymic Org., implanted thymic organoid.
doi:10.1371/journal.pmed.0050016.g003
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drugs have considerable potential for preventing HIV-1
transmission [42]. The expectation for pre-exposure prophy-
laxis is that antiretroviral drugs taken appropriately can
prevent HIV infection [4]. There is as yet no clinical evidence
for the effectiveness of this approach [43–46]. However,
precedent for the administration of antiretrovirals to large
populations of individuals at high risk for infection is
exemplified by the widespread use of nevirapine for the
prevention of mother-to-child transmission of HIV [47,48].
Similarly, if proven safe and effective, pre-exposure prophy-
laxis together with other behavioral interventions could
provide protection to men and women at risk of HIV
Figure 4. Changes in CD4þCCR5þ and CD8þCCR5þ Human T Cell Levels Resulting from HIV-1 Infection
(A) Comparison of the levels of human CD4þCCR5þ T cells in the indicated tissues in a representative naive BLT mouse, an HIV-1–infected, and an HIV-1–
exposed BLT mouse that received FTC/TDF for pre-exposure prophylaxis. Liver and lung were the examined tissues with the greatest constitutive CCR5
expression, and they both showed significant loss of CD4þCCR5þ T cells due to HIV-1 infection.
(B) Box plot depicting the levels of CD8þCCR5þ T cells in the indicated tissues for naive (green), HIV-1 infected (white), and FTC/TDF-treated plus HIV-1–
exposed (red) BLT mice.
(C) Comparison of the levels of human CD8þCCR5þ T cells in the indicated tissues in representative naive, HIV-1 infected and FTC/TDF treated BLT mice.
All tissues examined showed increases in CD8þCCR5þ T cells resulting from HIV-1 infection of BLT mice.
(D) Box plot depicting the levels of CD8þCCR5þ T cells in the indicated tissues for naive (green), HIV-1–infected (white), and FTC/TDF-treated plus HIV-1–
exposed (red) BLT mice. In the box plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data. The middle line
within each box indicates the median of the data, whereas the vertical line extends from lowest to the highest values. Naive (n¼ 5), HIV-1 infected (n¼
4), and FTC/TDFþHIV-1 (n¼ 3). Gating strategy for flow cytometric analysis: live cells! human CD45! human CD3! human CD4 or CD8! CCR5.
BM, bone marrow; LN, lymph node; PB, peripheral blood; Thymic Org., implanted thymic organoid.
doi:10.1371/journal.pmed.0050016.g004
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infection by preventing sexual transmission. Therefore, it is
critical to evaluate new prevention methods aimed at the
populations at highest risk. Despite the urgency to develop
and implement novel approaches capable of preventing HIV
transmission, this process has been hindered by the lack of
adequate animal models readily available for pre-clinical
efficacy and safety testing [49].
We investigated the possibility that BLT mice might serve
as an efficient, relatively fast, and cost-effective small animal
model of intravaginal HIV-1 infection. We demonstrate that
the female reproductive tract of BLT mice is populated with
in situ–generated human cells critical for the transmission
and dissemination of HIV-1. We observed that a single
intravaginal exposure to HIV-1 results in infection in 88% of
the exposed humanized BLT mice, demonstrating their
susceptibility to vaginal transmission. These observations
distinguish the BLT system (with its self-renewing, hemato-
poietic stem cell–based systemic human reconstitution,
including throughout the female reproductive tract) from
SCID mice injected with human peripheral blood lymphocyte
(SCID-hu PBL) with respect to vaginal HIV-1 transmission
[50,51]. The systemic nature of BLT human reconstitution
facilitated examination of the pathogenic effects caused by
infection in BLT mice. Our analyses revealed that HIV-1
Figure 5. Loss of CCR5þ and Effector Memory CD4þ T Cells from GALT during HIV-1 Infection
(A) Comparison of the levels of CD4þ or CD8þ human T cells in the GALT of representative naive and HIV-1–infected mice.
(B) Box plot depicting the levels of GALT CD4þ T cells for naive (green) and HIV-1–infected (white) BLT mice.
(C) Comparison of the levels of human CD4þCCR5þ T cells in the GALT of naive and HIV-1–infected BLT mice. Significantly fewer GALT CD4þ T cells had
detectable CCR5 expression levels following HIV-1 infection.
(D) Box plot depicting the levels of CD4þCCR5þ T cells in the GALT for naive (green) and HIV-1–infected (white) BLT mice.
(E and F) Comparison of the levels of human CD4þ effector memory T cells in the small intestine intra-epithelial (E) and lamina propria (F) lymphocyte
compartments of representative naive and HIV-1–infected BLT mice. HIV-1–infected BLT mice have statistically fewer effector memory CD4þ T cells
present in their small intestines.
(G) Box plot depicting the levels of CD45RAnegCD27neg effector memory T cells in the small intestine of naive (green) and HIV-1–infected (white) BLT
mice. In the box plots, the boxes extend from the first to the third quartiles, enclosing the middle 50% of the data. The middle line within each box
indicates the median of the data, whereas the vertical line extends from lowest to the highest values. Naive (n ¼ 4), HIV-1 infected (n ¼ 4). Gating
strategy for flow cytometric analysis: live cells ! human CD45 ! human CD3 ! human CD4 ! CCR5, CD27, or CD45RA.
IEL, intraepithelial lymphocytes; LI large intestine; LPL, lamina propria lymphocytes; SI, small intestine.
doi:10.1371/journal.pmed.0050016.g005
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disseminates from the vaginal mucosa to cause systemic CD4þ
T cell loss, including GALT CD4þ effector memory T cell loss,
as in humans [38]. Thus, humanized BLT mice represent a
useful model for HIV-1 intravaginal transmission, systemic
spread, and pathogenesis.
We utilized the fact that BLT mice are susceptible to
intravaginal HIV-1 infection to demonstrate that this system
is well suited for the preclinical evaluation of pre-exposure
prophylactic regimens to prevent intravaginal HIV-1 trans-
mission. Our results show that the BLT model can serve as a
relatively fast and simple system to test whether pre-exposure
prophylaxis can prevent vaginal HIV-1 transmission. Using
this system, we found that FTC/TDF can afford complete
protection from vaginal HIV-1 transmission. These results
suggest that the BLT model could also be suitable for testing
topical microbicides. Our results serve as preclinical evidence
for the potential success of this approach aimed at preventing
the further spread of AIDS.
As with all animal models of human disease, there are
limitations to this study. Although our findings are consistent
with findings from non-human primate research regarding
the potential of pre-exposure prophylaxis to prevent HIV-1
transmission [2,42], neither model has been shown to predict
efficacy or safety in humans. This is due to the lack of any
kind of data from similar pre-exposure prophylaxis in
humans. Therefore, an important limitation is that the BLT
model currently has no known predictive value for clinical
medicine. It is essential that this and future BLT studies be
validated against data from human clinical trials, some of
which are ongoing. Variables between humanized BLT mice
and humans include possible differences in drug concen-
trations, in adherence, in renal and liver biology, virus
dosage, and coinfections with viruses such as hepatitis B virus.
Although many aspects of HIV-1 GALT pathogenesis are
recapitulated in BLT mice, we have not determined whether
there is a direct and/or indirect pathologic effect of HIV-1 on
enterocytes, as seen in humans. Many of these limitations can
be addressed in future studies. In the interim, our data
support the potential for antiretrovirals in general and FTC/
TDF in particular to function as a pre-exposure prophylaxis
measure against the spread of HIV/AIDS in humans.
More women are being infected by HIV-1 now than at any
other time during the AIDS epidemic. The number of
infected women worldwide has increased to almost 15.4 [1].
Figure 6. Pre-exposure FTC/TDF Treatment Resulted in Complete Protection of Humanized BLT Mice from Intravaginal HIV-1 Transmission
(A) Box plot depicting real-time PCR levels of HIV-1 viral DNA in the indicated tissues for HIV-1–infected (white) and FTC/TDF-treated plus HIV-1–
exposed (red) BLT mice. (Viral DNA copies per million CD4þ T cells shown.) HIV-1 infected (n¼ 2) and FTC/TDFþ HIV-1 (n¼ 4).
(B) Box plot depicting virus rescue results from HIV-1–infected (white) and FTC/TDF-treated plus HIV-1–exposed (red) BLT mice. Virus rescue data
expressed as pg/ml of p24 per 13 105 CD4þ T cells cocultured with PHA/IL2-activated peripheral blood lymphocyte from a seronegative donor. HIV-1
infected (n¼ 2) and FTC/TDFþHIV-1 (n¼ 4). In the box plots, the middle line indicates the median of the data, whereas the vertical line extends from
lowest to the highest values. Dashed lines indicate the limit of detection for each assay.
(C) In situ hybridization analysis to determine the presence of productively HIV-1–infected cells in the indicated tissues from HIV-1–infected or FTC/TDF-
treated BLT mice (bars indicate 50 lm). Note the lack of HIV-1 in the BLT mice that received pre-exposure prophylaxis with FTC/TDF. HIV-1 infected (n¼
4) and FTC/TDFþ HIV-1 (n¼ 3).
BM, bone marrow; LPL, lamina propria lymphocytes; Thymic Org., implanted thymic organoid; SI, small intestine.
doi:10.1371/journal.pmed.0050016.g006
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As a female-controlled prevention measure, antiretroviral
pre-exposure prophylaxis and/or topical microbicides could
provide women with a powerful tool to protect themselves
from infection. However, any candidate drug(s) must be safe,
especially in individuals without disease, and efficacious and,
in order to be successful, must be easy to use [4]. The
combination of FTC/TDF appears to meet the criteria for
drugs to be used for pre-exposure prophylaxis [31]. In
addition, it is one of the few drug combinations that can be
administered once daily without food restrictions. In this
report, we provide preclinical evidence regarding the
potential efficacy of antiretroviral pre-exposure prophylaxis
in humans. Our results should provide further impetus for
the continued implementation of clinical trials using oral
antiretroviral pre-exposure prophylaxis, particularly in parts
of the world with highest HIV prevalence, where pre-
exposure prophylaxis would be most beneficial and cost
effective.
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Editors’ Summary
Background. Since the first cases of acquired immunodeficiency
syndrome (AIDS) in 1981, the AIDS epidemic has spread rapidly. About
33 million people are now infected with the human immunodeficiency
virus (HIV), the cause of AIDS. More than half of newly acquired infections
now occur in women, mostly through unprotected vaginal sex with an
infected male partner. Women are biologically more susceptible than
men to HIV infection during vaginal intercourse and often cannot
persuade their partner to use a condom. Consequently, alternative
strategies that prevent intravaginal transmission of HIV (infection
through the vagina) are urgently needed, particularly strategies that
women can use without their partner’s agreement. A vaccine would be
ideal but it could be many years before an effective HIV vaccine is
available so researchers are investigating other preventative strategies
such as the use of microbicides—compounds that protect against HIV
when applied inside the vagina—and pre-exposure treatment (prophy-
laxis) with antiretroviral drugs.
Why Was This Study Done? Before any new strategy to prevent
intravaginal HIV transmission is tried by women, it has to be tested in
animals. Currently, this can only be done in macaques, an expensive
option. In this study, the researchers have investigated whether
‘‘humanized BLT’’ mice could be used instead. When HIV enters the
human body during vaginal intercourse, it sticks to dendritic cells (a type
of immune system cell) in the vaginal lining. These cells carry the virus to
the body’s lymphoid tissues (collections of immune cells), where it
infects and kills CD4þ T cells (another type of immune cell). Dendritic cells
and CD4þ T cells have molecules on their surface that HIV recognizes.
Mice are not normally susceptible to infection with HIV because their
immune system cells lack these molecules. Humanized BLT mice have a
nearly human immune system—BLT stands for bone marrow, liver,
thymus. They are produced by implanting pieces of human fetal liver and
thymus (the organ where T cells learn to recognize foreign invaders)
under the kidney capsule of immunodeficient mice (animals born
without an immune system) and then transplanting human hemato-
poietic stem cells (the source of the major immune system cells) into the
mice.
What Did the Researchers Do and Find? When the researchers
examined the female reproductive tract of humanized BLT mice for
human immune system cells, they found CD4þ T cells, dendritic cells and
macrophages, all of which are involved in HIV infection. Furthermore,
half of the blood cells of the BLT mice were human. Most of the BLT
mice, the researchers report, were susceptible to intravaginal HIV
infection as shown, for example, by a rapid loss of human CD4þ T cells
from their blood. However, BLT mice pretreated with antiretroviral drugs
(a mixture of emtricitabine and tenofovir disoproxil fumarate) were
resistant to intravaginal HIV infection. As in human HIV infections, CD4þ T
cells were also depleted in several other organs of the BLT mice after
intravaginal HIV infection. Again, this depletion was prevented by
antiretroviral pre-exposure prophylaxis. Finally, human CD4þ T cells also
disappeared from the gut-associated lymphoid tissue (an important site
for HIV replication and CD4þ T cell depletion during human HIV disease)
of the BLT mice after infection with HIV.
What Do These Findings Mean? These findings show that humanized
BLT mice are susceptible to intravaginal infection with HIV and that many
aspects of HIV infection in these mice closely mimic infection in people.
In addition, by showing that pre-exposure prophylaxis with antiretroviral
drugs prevents HIV infection, these results suggest that humanized BLT
mice could be used to test new strategies designed to prevent
intravaginal infection. As with all animal models, any approach that
works in humanized BLT mice will still have to be tested in people.
Nevertheless, these findings provide preclinical evidence that pre-
exposure prophylaxis with antiretroviral drugs may be an effective way
to prevent intravaginal transmission of HIV and, therefore, provide
valuable support for clinical trials of this approach.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050016.
 Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS and on HIV infection in
women
 HIVInSite has comprehensive information on all aspects of HIV/AIDS,
including articles on women and HIV and on safer sex, which includes
information on pre-exposure prophylaxis and microbicides
 Information is available from Avert, an international AIDS charity, on
HIV prevention, on women, HIV, and AIDS, and on microbicides
 The US Centers for Disease Control and Prevention provides
information on HIV/AIDS, including information on HIV/AIDS among
women and on CDC trials of pre-exposure prophylaxis for HIV
prevention (in English and some information in Spanish)
 PrEP Watch is a comprehensive information source on pre-exposure
prophylaxis for HIV prevention
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